Xtampza ER is Collegium’s first product utilizing its proprietary DETERx® technology platform, and is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse.
Collegium is advancing clinical development of Hydrocodone DETERx, its second pipeline candidate. Based upon the results of a pilot, proof of concept clinical study and in vitro characterization, Hydrocodone DETERx is expected to provide similar advantages and unique product characteristics as Xtampza ER.
We also have other extended-release, abuse-deterrent product candidates that are in the preclinical phase of development, including oxymorphone and morphine for pain, and methylphenidate for the treatment of attention deficit hyperactivity disorder, or ADHD. We own exclusive rights to all of our DETERx product candidates.
Collegium also owns the U.S. rights to ONSOLIS® (fentanyl buccal soluble film). ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.